Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome

Pediatr Dermatol. 2007 Jan-Feb;24(1):42-5. doi: 10.1111/j.1525-1470.2007.00331.x.

Abstract

Netherton syndrome is a congenital skin disease associated with decreased skin barrier function and increased percutaneous absorption. We report an 11-year-old boy with Netherton syndrome who developed Cushing syndrome after application of 1% hydrocortisone ointment to his entire body for more than 1 year. This presentation illustrates that even low-potency steroid ointments should be used with caution in Netherton syndrome and warns about the use of long-term topical medications with potential systemic side effects when used in large quantities in any chronic skin disease.

Publication types

  • Case Reports

MeSH terms

  • Administration, Cutaneous
  • Anti-Inflammatory Agents / poisoning*
  • Anti-Inflammatory Agents / therapeutic use
  • Child
  • Cushing Syndrome / chemically induced*
  • Humans
  • Hydrocortisone / poisoning*
  • Hydrocortisone / therapeutic use
  • Male
  • Mutation
  • Ointments
  • Proteinase Inhibitory Proteins, Secretory / genetics
  • Pruritus / drug therapy
  • Serine Peptidase Inhibitor Kazal-Type 5
  • Skin Absorption
  • Skin Diseases, Genetic / drug therapy*
  • Syndrome

Substances

  • Anti-Inflammatory Agents
  • Ointments
  • Proteinase Inhibitory Proteins, Secretory
  • SPINK5 protein, human
  • Serine Peptidase Inhibitor Kazal-Type 5
  • Hydrocortisone